However, the market needs to separate what has been announced from what has been delivered. HIP 3 remains in the testnet phase, and regulatory approval for US operations is still outstanding. From a market perspective, the long-term opportunity is credible, but execution will determine whether it translates into lasting value for HYPE holders. I would prioritize confirmed adoption and regulatory progress over chasing short-term price momentum.
